Scienture Holdings (SCNX) Restructuring Costs (2021 - 2026)
Scienture Holdings' (SCNX) quarterly Restructuring Costs came in at $117815.0 in Q2 2026, down 69.13% year-over-year from $381683.0 in Q2 2025, and down 63.88% quarter-over-quarter from $326178.0 in Q1 2026.
Analysis
Scienture Holdings (SCNX) Restructuring Costs (2021 - 2026) Analysis & Trends
Scienture Holdings has disclosed Restructuring Costs across 6 years of filings, most recently posting $117815.0 for Q2 2026.
- In Q2 2026, Restructuring Costs fell 69.13% year-over-year to $117815.0; the TTM figure through Jun 2026 stood at $1.3 million (down 4.9% YoY), while the FY2025 annual figure was $2.1 million, up 14.57% from the prior year.
- Restructuring Costs came in at $117815.0 for Q2 2026 at Scienture Holdings, down from $326178.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $724386.0 in Q4 2023 to a low of $117815.0 in Q2 2026.
- Average Restructuring Costs over 5 years is $295997.8, with a median of $255742.5 recorded in 2022.
- Year-over-year, Restructuring Costs surged 175.15% in 2023 and tumbled 69.13% in 2026.
- Over 5 years, Restructuring Costs stood at $263269.0 in 2022, then surged by 175.15% to $724386.0 in 2023, then plunged by 76.3% to $171708.0 in 2024, then soared by 122.29% to $381683.0 in 2025, then slumped by 69.13% to $117815.0 in 2026.
- Per Business Quant data, the three most recent Restructuring Costs figures were $117815.0 in Q2 2026, $326178.0 in Q1 2026, and $381683.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 117,815.00 |
| Mar 31, 2026 | 326,178.00 |
| Jun 30, 2025 | 381,683.00 |
| Mar 31, 2025 | 470,825.00 |
| Jun 30, 2024 | 171,708.00 |
| Mar 31, 2024 | 339,047.00 |
| Dec 31, 2023 | 724,386.00 |
| Sep 30, 2023 | 408,957.00 |
| Jun 30, 2023 | 124,799.00 |
| Mar 31, 2023 | 248,216.00 |
| Dec 31, 2022 | 263,269.00 |
| Sep 30, 2022 | 191,007.00 |
| Jun 30, 2022 | 139,858.00 |
| Mar 31, 2022 | 236,221.00 |
| Dec 31, 2021 | 235,199.00 |
| Sep 30, 2021 | 98,867.00 |
| Jun 30, 2021 | 203,712.00 |
| Mar 31, 2021 | 160,047.00 |